rtmark
LearnBonds.com

Novartis in Trouble Again, Executive Sold Shares Before Drug Data Manipulation Case Came Out

Novartis in Trouble Again, Executive Sold Shares Before Drug Data Manipulation Case Came Out

Novartis, one of the most influential drug makers in the market, has landed itself in fresh trouble after revealing that an executive sold its share days before the Zolgensma drug data manipulation came out in public.

What happened at Novartis?

The unknown Novartis executive, as revealed by the company, sold share worth 925,400 Swiss Francs about three weeks before the US Food and Drug Administration (FDA) said that the data from Zolgensma gene therapy had been manipulated.

Novartis in Trouble Again, Executive Sold Shares Before Drug Data Manipulation Case Came Out

The company has previously announced the ouster of two brother scientists holding top positions in a subsidiary company that developed Zolgensma. It is unclear if either of the two brothers had sold their shares in the company. The company noted that they had not been involved in any of their projects since May when the drug was accepted by the FDA.

The news of the stock sale was first shared by SonntagsZeitung this Sunday. The company had included the sale in a Swiss stock exchange filing on July 19. According to the filing, a member of the executive committee or board of directors of Novartis sold their stock. A company spokesperson explained, “As is usual in such cases, the transaction was thoroughly checked beforehand and then approved accordingly. The person in question was not in possession of relevant material information.”

No wrongdoing in the sale

The chain of events following the stock sale looks odd prima facie even though Novartis spokesperson suggests that the person who sold the shares was not aware of the drug manipulation case. However, it must be noted that the sale was made on July 19 and Novartis informed the FDA about manipulation much before that. The FDA noted that after it approved the drug in May, the company came to them with news of manipulated data in June.

Only the public announcement of the scandal was made on August 6, following which the company’s shares tanked by 3%. According to the regulator, the company was aware of the early testing data manipulation to support the drug for about two months before the approval. It could now face civil or criminal penalties for the same.

The data used to compare the early version of the drug against its later versions. Note that the company had changed the manufacturing process of the drug because of which the data comparison was crucial. The FDA hasn’t put Zolgensma off the shelves as it believes that the comparison doesn’t impact the safety of the drugs.

Trusted & Regulated Stock & CFD Brokers

What we like

  • 0% Fees on Stocks
  • 5000+ Stocks, ETFs and other Markets
  • Accepts Paypal Deposits

Min Deposit

$200

Charge per Trade

Zero Commission

Rating

64 traders signed up today

Visit Now

75% of investors lose money when trading CFDs.

Available Assets

  • Total Number of Stocks & Shares5000+
  • US Stocks
  • German Stocks
  • UK Stocks
  • European
  • ETF Stocks
  • IPO
  • Funds
  • Bonds
  • Options
  • Futures
  • CFDs
  • Crypto

Charge per Trade

  • FTSE 100 Zero Commission
  • NASDAQ Zero Commission
  • DAX Zero Commission
  • Facebook Zero Commission
  • Alphabet Zero Commission
  • Tesla Zero Commission
  • Apple Zero Commission
  • Microsoft Zero Commission

Deposit Method

  • Wire Transfer
  • Credit Cards
  • Bank Account
  • Paypall
  • Skrill
  • Neteller

What we like

  • 0% Commission
  • Trade Stocks Via CFDs
  • Authorized & regulated by the FCA

Min Deposit

$100

Charge per Trade

Zero Commission

Rating

Visit Now

80.5% of retail investor accounts lose money when trading CFDs with this provider.

Available Assets

  • Total Number of Stocks & Shares+2000
  • US Stocks
  • German Stocks
  • UK Stocks
  • European
  • ETF Stocks
  • IPO
  • Funds
  • Bonds
  • Options
  • Future
  • CFDs
  • Crypto

Charge per Trade

  • FTSE 100 Zero Commission
  • NASDAQ Zero Commission
  • Dax Zero Commission
  • Facebook Zero Commission
  • Alphabet Zero Commission
  • Tesla Zero Commission
  • Apple Zero Commission
  • Microsoft Zero Commission

Deposit Method

  • Wire transfer
  • Credit Cards
  • Bank Account
  • Paypal
  • Skrill
All trading carries risk. Views expressed are those of the writers only. Past performance is no guarantee of future results. The opinions expressed in this Site do not constitute investment advice and independent financial advice should be sought where appropriate. This website is free for you to use but we may receive commission from the companies we feature on this site.
Avatar

Viraj loves to write and express his views on anything related to Finance, Crypto, or Fintech. He has been covering Finance & Crypto for more than five years now. He likes Tesla. He also writes on Healthcare, and Technology among other stuff.